Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2015', provides an overview of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 7
Therapeutics Development 8
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 8
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis 9
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 10
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes 11
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 14
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes 15
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 16
Arsanis Biosciences GmbH 16
ContraFect Corporation 17
Debiopharm International S.A. 18
ImmuVen, Inc. 19
Lytix Biopharma AS 20
PharmaIN Corporation 21
Sealife PHARMA GMBH 22
Sumitomo Dainippon Pharma Co., Ltd. 23
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ASN-100 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CF-301 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Debio-1450 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IMV-0123 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LTX-109 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PGC Anti-MRSA - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SLP-0904 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SLP-0905 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SM-295291 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SM-369926 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules for Bacterial Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
targocil - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Recent Pipeline Updates 48
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 52
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 53
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 54
Featured News & Press Releases 54
Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 54
May 01, 2012: ImmuVen Receives $1.68m Phase II SBIR Grant From NIH For MRSA Therapeutics 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2015 8
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015 16
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H2 2015 17
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International S.A., H2 2015 18
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ImmuVen, Inc., H2 2015 19
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Lytix Biopharma AS, H2 2015 20
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by PharmaIN Corporation, H2 2015 21
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 22
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Therapeutics - Recent Pipeline Updates, H2 2015 48
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2015 52
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2015 53